Summary
A chemotherapy regimen consisting of carboplatin and vinblastine was given to 30 patients with recurrent or previously untreated, locally advanced squamous carcinoma of the head and neck region. The main aim of the study was to assess the toxicity of this regimen, the feasibility of its out-patient administration and the tumour response. A total of ten patients (33%) achieved an objective response, including two who achieved a complete response. The combination offered useful palliation for patients with recurrent disease; it was well tolerated and can be given on an out-patient basis. This regimen could be combined with other active agents such as methotrexate or bleomycin.
This is a preview of subscription content, log in via an institution to check access.
References
Adams M, Kerby IJ, Rocker A, Evans A, Johansen K, Franks CR (1989) A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28: 57–60
Al-Sarraf M, Metch B, Kish J, Ensley J, Rinehart JJ, Schuller DE, Coltman CA (1987) Platinum analogues in recurrent advanced head and neck cancer: a South West Oncology Group and Wayne State study. Cancer Treat Rep 71: 723–726
American Joint Committee for Cancer Staging and End Results (1977). Reporting manual for staging of cancer, Chicago
Andres Basauri L de, Lopez Pousa A, Alba E, Sampedro F (1986) Carboplatin, an active drug in advanced head and neck cancer. Cancer Treat Rep 70: 1173–1176
Carter SK (1977) The chemotherapy of head and neck cancer. Semin Oncol 4: 413–424
Drelichman A, Cummings G, Al-Sarraf M (1983) A randomised trial of a combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced head and neck cancer. Cancer 52: 399–403
Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D (1986) Carboplatin (NSC 241-240): an active platinum analog for the treatment of squamous cell carcinoma of head and neck. J Clin Oncol 4: 1506–1509
Glick JH, Taylor SG (1981) Integration of chemotherapy into a combined modality treatment plan for head and neck cancer: a review. Int J Radiat Oncol 7: 229–242
Hong WK, Shaefer S, Issell B, Cummings C, Leudke D, Bromer R, Fofonoff S, D’Aoust J, Shapshay S, Welch J, Levin E, Vincent M, Vaughan C, Strong S (1983) A prospective randomised trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of head and neck. Cancer 52: 206–210
Kish JA, Weaver A, Jacobs J, Cummings C, Al-Sarraf M (1984) Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53: 1819–1824
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Wiltshaw E (1985) Ovarian trials at the Royal Marsden. Cancer Treat Rep 12 [Suppl A]: 67–71
Woods RL, Fox RM, Tattershall MHN (1981) Methotrexate treatment of squamous cell head and neck cancers: dose response evaluation. Br Med J 282: 600–602
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
EL Sayed, S., Symonds, R.P., Robertson, A.G. et al. Phase II trial of carboplatin and vinblastine in advanced squamous-cell carcinoma of the head and neck. Cancer Chemother Pharmacol 26, 464–466 (1990). https://doi.org/10.1007/BF02994101
Issue Date:
DOI: https://doi.org/10.1007/BF02994101